Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Braz. j. med. biol. res ; 43(2): 134-138, Feb. 2010. tab
Artigo em Inglês | LILACS | ID: lil-538228

RESUMO

The nature and frequency of cystic fibrosis mutations in Brazil is not uniform due to the highly varied ethnic composition of the population. The average frequency of the F508del mutation has been reported to be 48.6 percent. Other common mutations in Brazil are G542X, R1162X, and N1303K. The aim of this study was to analyze the frequency of 8 mutations (F508del, G542X, R1162X, N1303K, W1282X, G85E, 3120+1G>A, and 711+1G>T) in a sample of 111 newborn patients with cystic fibrosis diagnosed by the Cystic Fibrosis Neonatal Screening Program of Minas Gerais State. The mutations were tested by allele-specific oligonucleotide PCR with specially designed primers. An allele frequency of 48.2 percent was observed for the F508del mutation, and allele frequencies of 5.41, 4.50, 4.05, and 3.60 percent were found for the R1162X, G542X, 3120+1G>A, and G85E mutations, respectively. The genotypes obtained were in Hardy-Weinberg equilibrium. These data demonstrate that the 8-mutation panel studied here has extensive coverage (68 percent) for the cystic fibrosis mutations in Minas Gerais. These data improve our knowledge of cystic fibrosis in Brazil, particularly in this region. In addition, this investigation contributed to the establishment of a sensitive and population-specific mutation panel, which can be helpful for molecular diagnosis of cystic fibrosis.


Assuntos
Humanos , Recém-Nascido , Regulador de Condutância Transmembrana em Fibrose Cística/genética , Fibrose Cística/genética , Mutação/genética , Brasil , Fibrose Cística/sangue , Frequência do Gene , Genótipo , Triagem Neonatal , Análise de Sequência de DNA
2.
Genet. mol. res. (Online) ; 7(1): 74-84, Jan. 2008. ilus, tab
Artigo em Inglês | LILACS | ID: lil-553773

RESUMO

A late onset neurological syndrome in carriers of premutation in FMR1 gene was recently described. The condition was named fragile-X-associated tremor/ataxia syndrome (FXTAS) and includes intentional tremor, cerebellar ataxia, parkinsonism, and cognitive deficit. We ascertained the contribution of FMR1 premutation to the phenotypes ataxia, tremor and/or parkinsonism. Sixty-six men over 45 years old presenting these symptoms, isolated or combined, were tested. Also, 74 normal men, randomly chosen in the population, formed the control group. In the patient group, no premutation carrier was found, which is in agreement with other observed frequencies reported elsewhere (0-5% variation). No significant differences were found when comparing gray zone allele frequencies among target and control groups. The FXTAS contribution in patients with phenotypic manifestations of FXTAS was 15/748 (2%). The presence of gray zone alleles is not correlated with FXTAS occurrence.


Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Ataxia/diagnóstico , Doença de Parkinson/diagnóstico , Frequência do Gene , Proteína do X Frágil da Deficiência Intelectual/genética , Tremor/diagnóstico , Alelos , Ataxia/fisiopatologia , Ataxia/genética , Ataxia/patologia , Estudos de Casos e Controles , Doença de Parkinson/fisiopatologia , Doença de Parkinson/genética , Doença de Parkinson/patologia , Predisposição Genética para Doença , Tremor/fisiopatologia , Tremor/genética , Tremor/patologia
3.
Genet. mol. res. (Online) ; 5(1): 33-44, Mar. 31, 2006. tab, ilus
Artigo em Inglês | LILACS | ID: lil-449148

RESUMO

Phenylketonuria (PKU) is one of the few genetic diseases in which mental retardation can be prevented. Hence, diagnosis and treatment must be established early. PKU treatment consists of a phenylalanine-restricted diet supplemented with a phenylalanine-free mixture of amino acids. However, it is difficult to adhere to this diet. In the last decade, a better comprehension of the biochemistry, genetics and molecular basis of the disease, as well as the need for easier treatment, led to the development of several new therapeutic strategies for PKU. In the present study, we evaluated these new therapeutic options in terms of theoretical basis, methodologies, efficacy, and costs.


Assuntos
Humanos , Alimentos Formulados , Dieta com Restrição de Proteínas/métodos , Fenilalanina Hidroxilase , Fenilcetonúrias/dietoterapia , Alimentos/normas , Aminoácidos/administração & dosagem , Fenilalanina/administração & dosagem , Fenilcetonúrias/genética , Fenótipo , Paladar , Terapia Genética/métodos
4.
Genet. mol. res. (Online) ; 5(1): 16-23, Mar. 31, 2006. tab, ilus
Artigo em Inglês | LILACS | ID: lil-449150

RESUMO

In order to determine the phenylketonuria (PKU) mutation spectrum in the population of Minas Gerais State, Brazil, 78 unrelated PKU patients found by the neonatal screening program from 1993 to 2003 were tested for nine phenylalanine hydroxylase mutations. These mutations were selected due to their high frequencies in other Brazilian populations and in Portugal, where the largest contingent of the Caucasian component of the Brazilian population originated from. The most frequent mutations were V388M (21%), R261Q (16%), IVS10nt11 (13.4%), I65T (5.7%), and R252W (5%). The frequencies of the other four mutations (R261X, R408W, Y414C, and IVS12nt1) did not reach 2%. By testing these nine mutations, we were able to identify 64% of the PKU alleles in our sample. V388M frequency was higher than in any other known population and almost three times larger than that observed in Portugal, probably reflecting genetic drift. The mutation profile, as well as the relative frequency of the different mutations, suggest that the Minas Gerais population more closely resembles that of Portugal than do the other Brazilian populations that have already been tested.


Assuntos
Humanos , Recém-Nascido , Fenilalanina Hidroxilase/genética , Fenilcetonúrias/genética , Mutação/genética , Testes Genéticos , Brasil/epidemiologia , Eletroforese em Gel de Poliacrilamida , Fenilcetonúrias/epidemiologia , Triagem Neonatal
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA